A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers

NCT00000871 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

420

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
BIOLOGICAL: MN rgp120/HIV-1 and A244 rgp120/HIV-1
BIOLOGICAL: ALVAC-HIV MN120TMG (vCP205)
BIOLOGICAL: rgp120/HIV-1 SF-2

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)